ORBIMED ADVISORS LLC

Q2 2024 13F-HR Holdings

Location
New York, NY
Holdings as of
6/30/2024
Date filed
8/14/2024
Form type
13F-HR
Num holdings
114
Total value ($000)
$5,064,526
Net value change ($000)
-395,434 (-7.2%)
New positions
10
Sold out positions
14
Turnover %
8.3%
Sector allocation + QoQ delta (equities-only)

Holdings aggregated across other managers listed in the original SEC filing. View detailed breakdown

Prev filing: 5/15/2024 Next filing: 11/14/2024 SEC filing

Snapshot: Change Analysis

Compared to Q1 2024
Methodology: sector metrics are equities-only; instrument mix chart is ex-options; options exposure is shown separately. Why this matters.
Top Adds (Value $000, Stocks/ETFs)
ALNY 60,823 NEW
ITGR 40,436 NEW
THC 32,758 26.6%
ARGX 30,233 50.7%
BSX 27,886 12.4%
ELVN 27,733 17.5%
IONS 25,800 29.6%
LLY 24,968 8.9%
AMGN 24,124 133.8%
ISRG 22,565 11.5%
Top Reduces (Value $000, Stocks/ETFs)
BMRN -109,515 -98.1%
ALPINE IMMUNE SCIENCES, INC. -106,255 -100.0%
SRRK -54,535 -85.9%
XTNT -39,482 -46.2%
ESPR -36,739 -100.0%
JANX -36,150 -22.5%
EVH -35,619 -41.7%
APGE -32,852 -68.8%
PRAX -28,100 -100.0%
NPCE -27,100 -51.3%
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000): 34,207 (0.7% of total reported value)
How this table is calculated: SEC VALUE ($000) is used as reported. For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received. Column % is bucket-based: non-options share is calculated inside non-option total, options share is calculated inside options total. Details.
Filter:
Instrument:
Issuer Name Ticker Sector Industry Class History Value ($000) % Shares Shares Δ Shares Δ% Value Δ ($000) Value Δ% Principal Option Type